Bone Graft Immunology

Bone Graft Immunology - Graft Encounters

• Antigenicity: Allografts & xenografts possess antigens; autografts are non-immunogenic.
• Primary Antigens: Cell-surface Major Histocompatibility Complex (MHC/HLA) on donor cells.
• Host Response:
  • Cell-mediated: T-lymphocytes (e.g., cytotoxic T-cells) attack graft.
  • Humoral: B-lymphocytes produce antibodies against donor antigens.
• Processing Impact: Methods like freezing or irradiation reduce immunogenicity but may alter graft properties.

⭐ The most significant antigens triggering rejection in bone allografts are Class I and Class II MHC (HLA in humans) molecules expressed on donor cells.

Bone Graft Immunology - ID Tags & Donor Files

• Immune response primarily cell-mediated, targeting donor antigens.
• Key Antigens ("ID Tags"):
  • MHC (HLA in humans): Most critical.
    • Class I: On all nucleated cells.
    • Class II: On Antigen Presenting Cells (APCs); most potent stimulators.
  • ABO blood group antigens: On vascular endothelium.
  • Minor histocompatibility antigens.
• Graft Types & Immunogenicity:

Bone Graft Immunology - The Rejection Reaction

• Trigger: Donor Major Histocompatibility Complex (MHC) Class I & II antigens on allograft cells.
• Recognition:
  • Direct: Host T-cells vs. donor MHC on donor APCs.
  • Indirect: Host APCs process & present donor antigens to T-cells.
• Immune Response Pathway:

• Outcome: Inflammation, impaired healing, graft resorption, failure.

⭐ Fresh, cellular allografts elicit the strongest immune response; processing (freeze-drying, demineralization) reduces immunogenicity.

Bone Graft Immunology - Tweaking the Transplant

• Goal: Minimize host immune response to allografts/xenografts.
• Key Factors Influencing Immunogenicity:
  • Cellularity: Viable cells (osteocytes, marrow) are primary antigen source.
  • MHC/HLA Antigens: Expressed on donor cells, trigger T-cell mediated rejection.
  • Graft Type: Autograft (none) < Allograft (moderate) < Xenograft (high).
• Graft Processing to ↓ Immunogenicity:
  • Freezing (-20°C to -80°C) / Freeze-drying: Kills cells, preserves matrix. Most common.
  • Irradiation (e.g., 25 kGy): Sterilizes, devitalizes cells.
  • Washing/Solvent treatment: Removes cellular debris, lipids.
  • Decellularization: Removes cells, aims to preserve scaffold.

  ⭐ Fresh, unprocessed allografts elicit the strongest immune response due to viable donor cells expressing MHC antigens. oka

Bone Graft Immunology - Outcomes & Outlooks

• Graft Failure: Immune-mediated rejection due to donor Major Histocompatibility Complex (MHC) antigens on osteocytes, osteoblasts, and passenger leukocytes is a key concern for allografts, potentially leading to resorption or non-union.
• Strategies to Enhance Success:
  • Graft Processing: Freezing, freeze-drying, irradiation significantly ↓ antigenicity.
  • Autografts: Ideal, circumvent immune rejection.
  • Immunomodulation: Limited role in routine bone grafting due to systemic effects.
• Outlook: Focus on developing less immunogenic allografts and advanced tissue-engineered constructs.

⭐ Creeping substitution: Host cells gradually resorb and replace graft material, essential for successful allograft incorporation and remodeling over months to years.

High‑Yield Points - ⚡ Biggest Takeaways

• Fresh allografts are most immunogenic due to MHC (HLA) antigens on donor cells.
• Cell-mediated immunity (T-lymphocytes) is the primary mechanism of allograft rejection.
• Graft processing (e.g., freezing, freeze-drying, irradiation) reduces immunogenicity but can impair biological activity.
• Autografts are non-immunogenic (gold standard); xenografts are highly immunogenic.
• HLA matching is not routinely performed for bone allografts, unlike solid organ transplants.
• Immune response can lead to inflammation, graft resorption, and eventual failure.